ADGRF5 and colorectal carcinoma: To note, CRC patients with higher expression of ADGRF5 were characterized by a median survival time of 34 months for OS and 32 months for DFS when compared to CRC patients with lower expression of ADGRF5 whose median survival time was evaluated as 22 months for both OS and DFS.